Imara Inc
NASDAQ:IMRA
Imara Inc
NASDAQ:IMRA
Price:
21 USD
232.28%
Market Closed
Updated:
May 5, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of IMRA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IMRA
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
IMRA Competitors Multiples
Imara Inc Competitors
Imara Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Imara Inc
NASDAQ:IMRA
|
552m USD | 0 | 371 | -8.1 | -8 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
698.5B USD | 19.4 | 113.8 | 55.8 | 63.5 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.3 | 33.1 | 36.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
359.3B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
322.8B USD | 5.3 | 140 | 33.3 | 52.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.3 | 140.7 | 225.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.3 | 13.4 | 9.8 | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
173.2B CHF | 3 | 15.1 | 8.6 | 10.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157B USD | 2.9 | -508.1 | 12.6 | 20.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
